BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
BioTech Health X
  • September 19, 2022

Biotech NewsVirios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results

  • 5 minute read
In a shocking failure, Virios Therapeutics announced this morning pre-market that topline results from its FORTRESS (Fibromyalgia Outcome…
1 Shares
1
0
0
0
0
0
0
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
BioTech Health X
  • September 14, 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • 8 minute read
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
0 Shares
0
0
0
0
0
0
0
Mayo-Clinic-Gene-Accelerator
BioTech Health X
  • September 3, 2022

Biotech NewsMayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

  • 4 minute read
Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
0 Shares
0
0
0
0
0
0
0
SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
BioTech Health X
  • September 2, 2022

BioTech CEO InterviewsSyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections

  • 8 minute read
Our BioTech Health X CEO Series continues with an exclusive interview with Dr. Emil Tsai of SyneuRx. Today…
11 Shares
11
0
0
0
0
0
0
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
BioTech Health X
  • August 1, 2022

Biotech NewsKrystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

  • 3 minute read
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
0 Shares
0
0
0
0
0
0
0
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
BioTech Health X
  • July 28, 2022

Biotech NewsImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

  • 3 minute read
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
1 Shares
1
0
0
0
0
0
0
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
BioTech Health X
  • July 22, 2022

Biotech NewsBrickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

  • 3 minute read
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
1 Shares
1
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
BioTech Health X
  • July 20, 2022

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • 3 minute read
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
Ocugen Announces FDA Clinical Hold Removal for Phase 2:3 COVAXIN BBV152 Clinical Trial
BioTech Health X
  • May 23, 2022

Biotech NewsOcugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial

  • 3 minute read
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News
BioTech Health X
  • April 20, 2022

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • 5 minute read
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Legend Biotech Appoints Dr Guowei Fang Head of Global Research and Early Development
BioTech Health X
  • April 1, 2022

Biotech NewsLegend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development

  • 2 minute read
Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
0 Shares
0
0
0
0
0
0
0
2seventy-bio-Secure-170-Million-Extending-Cash-Runway-Into-2025
BioTech Health X
  • March 16, 2022

Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025

  • 3 minute read
2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell…
0 Shares
0
0
0
0
0
0
0
Inhibikase-Therapeutics-Present-Phase-1-1b-Trial-Results-ADPD-Alzheimers-Parkinsons-Diseases-Conference
BioTech Health X
  • March 11, 2022

Biotech NewsInhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference

  • 3 minute read
Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be…
12 Shares
11
1
0
0
0
0
0
Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported
BioTech Health X
  • March 7, 2022

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • 2 minute read
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
0 Shares
0
0
0
0
0
0
0
Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team
BioTech Health X
  • February 14, 2022

Biotech NewsCellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs

  • 6 minute read
With the appointments of these experts, the firm has added to its industry knowledge, including Chief Scientific Officer…
0 Shares
0
0
0
0
0
0
0
Nasdaq Biotechnology Index Adds Quantum-Si Nasdaq QSI Life Sciences Company
BioTech Health X
  • December 14, 2021

Biotech NewsNasdaq Biotechnology Index Adds Quantum-Si (Nasdaq: QSI) Life Sciences Company

  • 1 minute read
Quantum-Si (Nasdaq: QSI), a life science instrumentation firm commercializing a distinctive protein sequencing technology, has been added to…
1 Shares
1
0
0
0
0
0
0
Sigilon Therapeutics Provides Update on Strategic Reprioritization
BioTech Health X
  • December 13, 2021

Biotech NewsSigilon Therapeutics Provides Update on Strategic Reprioritization

  • 2 minute read
The company will continue to focus on platform optimization, with a particular emphasis on MPS-1 and diabetes. The…
0 Shares
0
0
0
0
0
0
0
Xontogeny-CEO-Chris-Garabedian-Interiew-BioTech-Health-X
BioTech Health X
  • September 29, 2021

BioTech CEO InterviewsXontogeny CEO Chris Garabedian Exclusive Interview [September 2021]

  • 5 minute read
As we expand our coverage of the biotechnology sector with the latest biotech news, our team at BioTech…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
    MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
    • September 7, 2021
  • Infinity Pharmaceuticals Add 2 New Members to Board of Directors
    Infinity Pharmaceuticals Add 2 New Members to Board of Directors
    • September 7, 2021
  • Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    • September 7, 2021
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top